Arsenal acquires BresMed

The acquisition of BresMed is the first in a series of investments Arsenal plans to make to form a new platform in the market access, health economics and outcomes research, patient preference, and evidence sectors.

Arsenal’s investment in BresMed is made in partnership with a team of senior executives led by Jon Williams, former CEO of Evidera.

The firm is currently investing from Arsenal Capital Partners V, which closed on $2.36bn in April 2019. The fund was 27% deployed as of December 2019. Arsenal invests $50-300m of equity in healthcare and healthcare-related companies with EBITDA of at least $10m.

Company
Established in 2006, BresMed provides health economics research, communications, and consulting services to the global pharmaceutical industry. Headquartered in Sheffield, the company had office in Manchester, India, the Netherlands, Ireland and the US and around 150 staff as of 31 March 2019.

The company generated an operating loss of £42,507 from revenue of £11.7m for the year ending on 31 March 2019, down from an operating profit of £223,718 from revenue of £11.2 for the preceding year.

People
Arsenal Capital Partners - Gene Gorbach (investment partner).
BresMed Health Solutions – Nic Brereton (CEO, founder).

Advisers
Equity – Ropes & Gray (legal).
Company – Achelous Partners (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Support services
• United Kingdom
• Ropes & Gray
• Management Buy-in